B. longum R0175
Depressive Disorder, Major
Medical University of Lublinother_biologicalN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 81/ 100
Competitive context
22 Active assets in the Depressive Disorder, Major cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Amitriptyline Janssen Research & Development, LLC | Phase 4 | BBB |
Pregabalin Janssen Research & Development, LLC | Phase 4 | BBB |
S-Ketamine Janssen Research & Development, LLC | Phase 4 | BBB |
Seroquel® Janssen Research & Development, LLC | Phase 4 | BBB |
Paroxetine Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 4 | BB |
View all 50 →
Same molecule, other indications
B. longum R0175 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →